Table 1 Expression of NK-activating... | American Society of Hematology

Table 1

Expression of NK-activating receptors on CD8⁺ T LGLL patients

NKR	Patient 1	Patient 2	Patient 3	Patient 4	Patient 5	Patient 6	Patient 7	Patient 8	Patient 9	Patient 10	Mean controls,* n = 10	SD	P†
NKG2D			76	76	67	92	43		98	81	28.1	5.2	.001
CD94	28		34		62		39	90	61	45	15.6	5.6	.049
NKG2C	25				38			86	6	6	4.3	2.1	.162
NKp44			5							10	1.2	1.0	.241
NKp46		11	35					3	33	14	1.7	1.1	.005
NKp30		7	5	73				4	6	7	1.4	0.8	.006
KIR2DL1/2DS1‡					8	4				4	0.6	0.5	.677
KIR2DL2/3
2DS2§					10	91			89		2.8	1.6	.821
KIR2DS4‖		14						23			2.1	0.9	.496
KIR3DL1¶											0.9	0.7	.406

NKR	Patient 1	Patient 2	Patient 3	Patient 4	Patient 5	Patient 6	Patient 7	Patient 8	Patient 9	Patient 10	Mean controls,* n = 10	SD	P†
NKG2D			76	76	67	92	43		98	81	28.1	5.2	.001
CD94	28		34		62		39	90	61	45	15.6	5.6	.049
NKG2C	25				38			86	6	6	4.3	2.1	.162
NKp44			5							10	1.2	1.0	.241
NKp46		11	35					3	33	14	1.7	1.1	.005
NKp30		7	5	73				4	6	7	1.4	0.8	.006
KIR2DL1/2DS1‡					8	4				4	0.6	0.5	.677
KIR2DL2/3
2DS2§					10	91			89		2.8	1.6	.821
KIR2DS4‖		14						23			2.1	0.9	.496
KIR3DL1¶											0.9	0.7	.406

CD8⁺/CD3⁺ mean percentage positive and SD of the reference control group (n = 10) of a similar age range. (Note: Where percentage is shown, the percentage of CD3⁺/CD8⁺/ NKR⁺ cells was more than 2 SD above the mean of CD3⁺/CD8⁺ T cells from the control group.)

†

Median difference between the patient and the control groups was tested using Mann-Whitney-Wilcoxon statistics.

‡

Antibody reaction with anti-CD158a that recognizes KIR2DL1 (inhibitory) and KIR2DS1 (activating) receptors.

Antibody reaction with anti-CD158b that recognizes KIR2DL2, KIR2DL3 (both inhibitory), and KIR2DS2 (activating) receptors.

‖

Antibody reaction with anti-KARp50 that recognizes KIR2DS4.

Antibody reaction with anti-NKB1 that recognizes KIR3DL1.

View Large

This Feature Is Available To Subscribers Only